NASDAQ:RDNT - RadNet Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$14.10 +0.07 (+0.50 %)
(As of 08/17/2018 04:00 PM ET)
Previous Close$14.05
Today's Range$13.90 - $14.20
52-Week Range$8.05 - $15.50
Volume229,000 shs
Average Volume256,406 shs
Market Capitalization$678.40 million
P/E Ratio48.62
Dividend YieldN/A
RadNet logoRadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the imaging industry, including picture archiving communications systems; and provides teleradiology services for remote interpretation of images on behalf of radiology groups, hospitals, and imaging center customers. As of December 31, 2017, it operated 297 facilities directly or indirectly through joint ventures with hospitals in California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.

Receive RDNT News and Ratings via Email

Sign-up to receive the latest news and ratings for RDNT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Medical laboratories


Debt-to-Equity Ratio4.49
Current Ratio1.06
Quick Ratio1.06


Trailing P/E Ratio48.62
Forward P/E Ratio38.11
P/E Growth4.81

Sales & Book Value

Annual Sales$922.19 million
Price / Sales0.74
Cash Flow$1.7669 per share
Price / Cash7.98
Book Value$1.47 per share
Price / Book9.59


EPS (Most Recent Fiscal Year)$0.29
Net Income$50,000.00
Net Margins-0.64%
Return on Equity17.00%
Return on Assets1.84%


Outstanding Shares48,280,000
Market Cap$678.40 million

RadNet (NASDAQ:RDNT) Frequently Asked Questions

What is RadNet's stock symbol?

RadNet trades on the NASDAQ under the ticker symbol "RDNT."

How were RadNet's earnings last quarter?

RadNet Inc. (NASDAQ:RDNT) posted its quarterly earnings data on Thursday, August, 9th. The medical research company reported $0.11 earnings per share for the quarter, missing analysts' consensus estimates of $0.13 by $0.02. The medical research company had revenue of $244.40 million for the quarter, compared to analyst estimates of $239.34 million. RadNet had a positive return on equity of 17.00% and a negative net margin of 0.64%. The firm's revenue was up 6.3% compared to the same quarter last year. During the same period in the previous year, the business posted $0.11 earnings per share. View RadNet's Earnings History.

When is RadNet's next earnings date?

RadNet is scheduled to release their next quarterly earnings announcement on Thursday, November, 8th 2018. View Earnings Estimates for RadNet.

What price target have analysts set for RDNT?

3 analysts have issued 12 month price objectives for RadNet's shares. Their predictions range from $14.00 to $15.00. On average, they expect RadNet's share price to reach $14.6667 in the next year. This suggests a possible upside of 4.0% from the stock's current price. View Analyst Price Targets for RadNet.

What is the consensus analysts' recommendation for RadNet?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RadNet in the last year. There are currently 1 buy rating and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Strong Buy." View Analyst Ratings for RadNet.

Who are some of RadNet's key competitors?

Who are RadNet's key executives?

RadNet's management team includes the folowing people:
  • Mr. Howard G. Berger, Chairman, Pres, CEO & Treasurer (Age 72)
  • Mr. Mark D. Stolper, Exec. VP & CFO (Age 47)
  • Mr. Jeffrey L. Linden, Exec. VP & Gen. Counsel (Age 75)
  • Mr. Norman R. Hames, Pres, COO of Western Operations & Director (Age 62)
  • Mr. Stephen M. Forthuber, Pres & COO of Eastern Operations (Age 57)

Has RadNet been receiving favorable news coverage?

Media headlines about RDNT stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. RadNet earned a coverage optimism score of 0.11 on Accern's scale. They also assigned news coverage about the medical research company an impact score of 46.24 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for RadNet.

Who are RadNet's major shareholders?

RadNet's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.29%), Renaissance Technologies LLC (5.01%), Dimensional Fund Advisors LP (3.24%), FMR LLC (2.98%), Robotti Robert (1.68%) and Beck Mack & Oliver LLC (1.26%). Company insiders that own RadNet stock include David L Swartz, Jeffrey L Linden, John V Crues, Lawrence L Levitt, Mark Stolper, Marvin S Cadwell, Michael L Md Sherman, Michael N Murdock, Norman R Hames, Sandy Nyholm Kaminsky and Stephen M Forthuber. View Institutional Ownership Trends for RadNet.

Which institutional investors are selling RadNet stock?

RDNT stock was sold by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc., California Public Employees Retirement System, Acadian Asset Management LLC, Beck Mack & Oliver LLC, Campbell & CO Investment Adviser LLC, Robotti Robert, Macquarie Group Ltd. and Engineers Gate Manager LP. Company insiders that have sold RadNet company stock in the last year include David L Swartz, Jeffrey L Linden, John V Crues, Lawrence L Levitt, Mark Stolper, Marvin S Cadwell, Michael L Md Sherman, Michael N Murdock, Norman R Hames, Sandy Nyholm Kaminsky and Stephen M Forthuber. View Insider Buying and Selling for RadNet.

Which institutional investors are buying RadNet stock?

RDNT stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Renaissance Technologies LLC, BlackRock Inc., Phocas Financial Corp., ClariVest Asset Management LLC, Mackay Shields LLC, Cadence Capital Management LLC and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for RadNet.

How do I buy shares of RadNet?

Shares of RDNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is RadNet's stock price today?

One share of RDNT stock can currently be purchased for approximately $14.10.

How big of a company is RadNet?

RadNet has a market capitalization of $678.40 million and generates $922.19 million in revenue each year. The medical research company earns $50,000.00 in net income (profit) each year or $0.29 on an earnings per share basis. RadNet employs 7,440 workers across the globe.

How can I contact RadNet?

RadNet's mailing address is 1510 COTNER AVENUE, LOS ANGELES CA, 90025. The medical research company can be reached via phone at 310-478-7808 or via email at [email protected]

MarketBeat Community Rating for RadNet (NASDAQ RDNT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  219 (Vote Outperform)
Underperform Votes:  190 (Vote Underperform)
Total Votes:  409
MarketBeat's community ratings are surveys of what our community members think about RadNet and other stocks. Vote "Outperform" if you believe RDNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.